Mar 30, 2020 / 12:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Biohaven NURTEC Prevention Top Line Results Conference Call. (Operator Instructions) Please be advised that today's conference call may be recorded.
I would now like to hand the conference over to the Biohaven Chief Operating Officer, Clifford Bechtold. Thank you, and please go ahead.
Clifford Bechtold - Biohaven Pharmaceutical Holding Company Ltd. - President & GM of Biohaven Ireland and Chief Compliance Officer
Thank you, and welcome to the Biohaven conference call to discuss the top line data from the pivotal trial of NURTEC for the preventive treatment of migraine. Joining this call from multiple locations are Dr. Vlad Coric, our Chief Executive Officer; Dr. Richard Lipton, Professor and Vice Chair of Neurology at the Albert Einstein College of Medicine and Montefiore Health Systems and Director of the Montefiore Headache Center; Dr. Robert Croop, our Chief Development Officer in Neurology; and Jim Engelhart, Biohaven Chief Financial Officer.
This morning, we issued a press release
Biohaven Pharmaceutical Holding Company Ltd - Rimegepant Migraine Prevention Topline Data Webcast Transcript
Mar 30, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers